慢性血栓栓塞性肺动脉高压的新干预措施
本文综述慢性血栓栓塞性肺动脉高压(CTEPH)的三种治疗选择:肺动脉内膜剥脱术、球囊肺动脉成形术和PAH靶向药物。手术为可手术患者的确定性治疗,住院死亡率低于5%,3年生存率90%;球囊肺动脉成形术针对远端病变,血流动力学改善与手术相当;Riociguat随机对照试验显示可降低血管阻力并增加步行距离,已获批用于不可手术患者。
要点
- 疑似CTEPH应转诊至肺动脉高压专科中心确诊。
- 可手术患者首选肺动脉内膜剥脱术,住院死亡率<5%,3年生存率90%。
- 不可手术患者可选球囊肺动脉成形术或Riociguat,部分需联合治疗。
核心结论
- CTEPH有三种治疗选择:肺动脉内膜剥脱术、球囊肺动脉成形术和PAH靶向药物,均能降低肺动脉压力和血管阻力。
- 当前指南推荐手术为技术可手术患者的确定性治疗。
- 球囊肺动脉成形术在经验丰富的中心可达到与手术相当的血流动力学改善,但长期结局仍在评估中。
- Riociguat随机对照试验显示可降低不可手术CTEPH患者的血管阻力并增加步行距离,该药已获批用于这些患者。
- 部分患者可能从联合治疗中获益。
研究设计与样本
- 本文为综述,未报告系统检索范围。
主要发现
- 肺动脉内膜剥脱术涉及深低温循环停跳,住院死亡率<5%,3年生存率90%。
- 大型病例系列显示手术后血流动力学参数显著改善,并有明显的症状和预后获益。
- 球囊肺动脉成形术由日本心脏病学家在过去5年中改进,针对不可手术患者的更远端亚段病变,在经验丰富的中心并发症率低。
- Riociguat随机对照试验证明可降低不可手术CTEPH患者的血管阻力并增加步行试验距离。
关键数值与推荐
- 当前指南推荐手术为技术可手术CTEPH患者的确定性治疗。
- Riociguat已获批用于不可手术CTEPH患者。
临床怎么用
- 疑似CTEPH患者应转诊至肺动脉高压专科中心以确认诊断。
- 根据梗阻解剖水平选择治疗:手术、球囊肺动脉成形术或PAH靶向药物。
- 可手术患者首选肺动脉内膜剥脱术。
- 不可手术患者可考虑球囊肺动脉成形术或Riociguat,部分患者可能需联合治疗。
局限性
- 球囊肺动脉成形术的长期结局仍在评估中。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic thromboembolic pulmonary hypertension (CTEPH) can be defined as a type of precapillary pulmonary hypertension (PH) resulting from incomplete resolution of pulmonary embolism. Symptoms are exertional breathlessness and most patients come to a cardiologist's attention with a dilated right heart on echocardiography. Patients with suspected CTEPH should be referred for evaluation to a PH specialist centre to confirm the diagnosis. There are now three treatment options available, dependent on the anatomical level of the obstruction: pulmonary endarterectomy surgery, balloon pulmonary angioplasty and pulmonary arterial hypertension (PAH)-targeted drugs. All reduce pulmonary artery pressure and vascular resistance. Current guidelines recommend surgery as the definitive treatment in technically operable patients. The operation involves deep hypothermic circulatory arrest, but the in-hospital mortality is <5% and the 3-year survival is 90%. Large case series have demonstrated dramatic improvement in haemodynamic parameters with significant symptomatic and prognostic benefits. Balloon pulmonary angioplasty is the newest treatment that has been refined by Japanese cardiologists over the last 5 years. This technique is designed to target more distal subsegmental lesions in inoperable patients and in experienced centres has been shown to deliver equivalent haemodynamic improvement to surgery with low complication rates, but longer term outcome is still under evaluation. A recent randomised controlled trial has demonstrated a reduction in vascular resistance and increase in walk test distance with the PAH-targeted drug Riociguat in patients with inoperable CTEPH, and this drug is now licensed for these patients. It is likely that some patients will benefit from combinations of treatments.
引用
- Jenkins D. New interventions to treat chronic thromboembolic pulmonary hypertension. Heart. 2018. PMID: 29636403. doi:10.1136/heartjnl-2017-312110
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。